Cite
HARVARD Citation
Zhou, Y. et al. (2019). First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. Journal for immunotherapy of cancer. 7 (1), p. . [Online].